The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: Comparison of stages in lesion evolution

Journal of Neuropathology and Experimental Neurology

Volumn 55, Issue 12, 1996, Pages 1194-1204

  Cuzner, M Louise ^a   Gveric, Djordje ^a   Strand, Catherine ^a   Loughlin, A Jane ^a   Paemen, Liesbet ^b   Opdenakker, Ghislain ^b   Newcombe, Jia ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Metalloproteases; Multiple sclerosis; Plasminogen activator

Indexed keywords

GELATINASE; GELATINASE B; METALLOPROTEINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; ASTROCYTE; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATION; FEMALE; FOAM CELL; HUMAN; HUMAN TISSUE; MALE; MICROGLIA; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; WHITE MATTER;

EID: 0029907622     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005072-199612000-00002     Document Type: Article

References (37)

1. Cuzner ML, Davison AN, Rudge P. Proteolytic enzyme activity of blood leucocytes and CSF in multiple sclerosis. Ann Neurol 1978;4: 337-44
2. Alvord EC, Hruby S, Sires LR. Degradation of myelin basic protein by cerebrospinal fluid: Preservation of antigenic determinants under physiological conditions. Ann Neurol 1979;6:474-82
3. Cammer W, Bloom BR, Norton WT, Gordon S. Degradation of basic protein in myelin by neutral proteases secreted by stimulated macrophages: A possible mechanism of inflammatory demyelination. Proc Natl Acad Sci USA 1978;75:1554-58
4. Cammer W, Brosnan CF, Basile C, Bloom BR, Norton WT. Complement potentiates the degradation of myelin proteins by plasmin: Implications for a mechanism of inflammatory demyelination. Brain Res 1986;364:91-101
5. Gijbels K, Proost P, Masure S, Carton H, Billiau A, Opdenakker G. Gelatinase B is present in the crebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J Neurosci Res 1993;36:432-40
6. Proost P, Van Damme J, Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Comm 1993;192:1175-81
7. Gijbels K, Masure S, Carton H, Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 1992;41:29-34
8. Paemen L, Olsson T, Soderstrom M, Damme JV, Opdenakker G. Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases. Eur J Neurol 1994;1:55-63
9. Opdenakker G, Van Damme J. Cytokines and proteases in invasive processes: Molecular similarities between inflammation and cancer. Cytokine 1992;4:251-58
10. Murphy G, Docherty AJP. The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol 1992;7:120-25
11. Opdenakker G, Van Damme J. Cytokine-regulated proteases in autoimmune diseases. Immunol Today 1994;15:103-6
12. Opdenakker G, Masure S, Grillet B, Van Damme J. Cytokine-mediated regulation of human leukocyte gelatinases and their role in arthritis. Lymphokine Cytokine Res 1991;10:317-24
13. Gearing AJH, Beckett P, Christodoulou M, et al. Processing of tumor necrosis factor-α precursor by metalloproteinases. Nature 1994;370:555-57
14. Gijbels K, Galardy RE, Steinman L. Reversal of experimental allergic encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 1994;94:2177-82
15. Hewson AK, Smith T, Leonard JP, Cuzner ML. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflammation Res 1995;44: 345-49
16. Norga K, Paemen L, Masure S, et al. Prevention of acute autoimmune encephalomyelitis and abrogation of relapses in murine models of multiple sclerosis by the protease inhibitor D-penicillamine. Inflammation Res 1995;44:529-34
17. Matrisian LM. The matrix-degrading metalloproteinases. BioEssays 1992;14:455-63
18. Newcombe J, Cuzner ML. Monoclonal antibody 14E identifies the oligodendrocyte cell body in normal adult human and rat white matter. J Neuroimmunol 1988;16:11-20
19. Li H, Newcombe J, Cuzner ML. Characterisation and distribution of phagocytic macrophages in MS plaques. Neuropathol Appl Neurobiol 1993;19:214-23
20. Paemen L, Martens P, Masure S, Opdenakker G. Monoclonal antibodies specific for natural human neutrophil gelatinase B used for affinity purification, quantitation by two-site ELISA and inhibition of enzymatic activity. Eur J Biochem 1995;234:759-65
21. Van Noorden S. Problems and solutions. In: Beesley JE, ed. Immunocytochemistry: Practical approach. Oxford, UK: IRL Press, 1993:207-39
22. Newcombe J, Woodroofe MN, Cuzner ML. Distribution of glial fibrillary acidic protein in gliosed human white matter. J Neurochem 1986;47:1713-39
23. Woodroofe MN, Cuzner ML. Cytokine mRNA expression in inflammatory multiple sclerosis lesions: Detection by non-radioactive ISH. Cytokine 1993;5:583-88
24. Wilhelm SM, Collier IE, Marmer BL, Eisen AZ, Grant GA, Goldberg GI. SV40-transformed human lung fibroblasts secrete a 92-k Da type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem 1989;264:17213-21
25. Ware JH, Dibenedetto AJ, Pittman RN. Localization of tissue plasminogen activator mRNA in adult rat brain. Brain Res Bull 1995;37:275-81
26. Tsirka SE, Gualandris A, Amaral DG, Strickland S. Exitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 1995;377:340-44
27. Romanic AM, Madri JA. Extracellular matrix-degrading proteinases in the nervous system. Brain Pathol 1994;4:145-56
28. Said G, Hontebeyrie-Joskowicz M. Nerve lesions induced by macrophage activation. Res Immunol 1992;143:589-99
29. Koolwijk P, Miltenburg AMM, Van Erck MGM, Oudshoorn M, Niedbala MJ, Breedveld FC, Van Hinsbergh VWM. Activated gelatinase-B (MMP-9) and urokinase-type plaminogen activator in synovial fluids of patients with arthritis. Correlation with clinical and experimental variables of inflammation. J Rheumatol 1995;22: 385-93
30. Gijbels K, Steinman L. Gelatinase B producing cells in multiple sclerosis lesions. J Cell Biochem 1994;Suppl 18D:143
31. Maeda A, Sobel RA. Matrix metalloproteinases in the normal human central nervous system, microglial modules and multiple sclerosis lesions. J Neuropathol Exp Neurol 1996;55:300-309
32. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinase activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-2503
33. Cannella B, Raine SC. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995;37:424-35
34. Martel-Pelletier J, McCollum R, Fujimoto N, Obata K, Cloutier J, Pelletier J. Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab Invest 1994;70:807-15
35. Montgomery AMP, Sabzervari H, Reisfeld RA. Production and regulation of gelatinase B by human T-cells. Biochem Biophys Acta 1993;1176:265-68
36. Lacraz S, Isler P, Vey E, Welgus HG, Dayer J. Direct contact between T lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression. J Biol Chem 1994;269: 22027-33
37. Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 1995;154:4379-89